Case study · Pharma compliance software · Ireland into Europe
42 sales qualified leads for an early-stage AI platform in pharma compliance.
An early-stage AI platform for pharma compliance was up against established vendors. Buyers worried about data security, about AI replacing expert judgement, and about switching from tools they already used. So each segment got its own message.
Led by our founder · Figures from the client’s report · Name withheld
- Industry
- Pharma compliance software
- Based in
- Ireland
- Markets
- Europe and global pharma
- Length
- 6 months
- Channels
- LinkedIn and email

At a glance
Pharma compliance software · Ireland
The client and the goal
- The client
- An early-stage AI platform for pharma compliance in Ireland, a team of 2 to 10.
- Who they sell to
- R&D managers, compliance officers, quality assurance managers and C-suite at large pharma companies, smaller firms and independent consultants.
- The goal at the start
- Reach decision makers their own LinkedIn messages and articles were not reaching, against established vendors.
- The message angle
- One message per segment: faster documents and compliance for big pharma; regulatory help and process automation for smaller firms and consultants.
The market
From Ireland into European pharma.
- Ireland: the client’s base
- Europe: the target market
Countries shaded from the report’s target, “Europe and global pharma”; Russia and Turkey are left plain because the report does not say how far east it went. Map data: Natural Earth.
What we did
Researched 5,500 contacts by hand.
R&D, compliance, QA and C-suite contacts, each researched by hand and segmented by role and by company size.
R&DComplianceQAC-suiteSegmented by roleand by company sizeWrote one message per segment.
Big pharma heard about faster documents and compliance management. Smaller firms and independent consultants heard about regulatory help and process automation.
1Big pharma: faster documents and compliance
2Smaller firms and consultants: regulatory help
3Refined as the replies came in
Each group got its own message.
Ran LinkedIn and email side by side.
Both channels ran together for 6 months.
LinkedInEmail123456Six months, both channels every month; the strip shows time, not results.
What the work looked like
Job title
Segmented by
Geography
- inLinkedInside by side with email
- @Emailside by side with LinkedIn
Results
Exhibit 1
About one in 131 contacts researched by hand became a qualified lead.
The campaign, stage by stage
20% of LinkedIn invitations
19% of connections wrote back
The figures leave room for the result: 5,500 people x 20% accepted x 19% replied is at most about 210 replies, and 42 became qualified leads (our arithmetic). A qualified lead is a buyer who fits the brief and agreed to talk.
See the numbers
| Reached | 5,500 |
|---|---|
| Accepted | 20% |
| Replied | 19% |
| Qualified | 42 |
Exhibit 2
Acceptance and replies both ran at about the median for LinkedIn campaigns.
This campaign against public benchmarks, %
MedianHeyReach strong rangeThis campaign
Invitations acceptedHeyReach 2026, 96,051 campaigns
New connections who repliedHeyReach 2026, reply to acceptance
Benchmarks from HeyReach, LinkedIn Outreach Benchmark Report 2026 (96,051 campaigns).
See the numbers
| Invitations accepted: this campaign | 20% |
|---|---|
| Invitations accepted: median, HeyReach strong range | 20.75%, 31.78% |
| Replied: this campaign | 19% |
| Replied: median, HeyReach strong range | 18.1%, 28.89% |
What slowed results
What slowed it
Buyers worried about data security, about AI replacing expert judgement, and about why they should switch from the compliance tools they already used.
What changed
Each segment got its own message: big pharma heard about faster documents and compliance, smaller firms and consultants about regulatory help. Copy was refined as replies came in.
What you can take from this
- Answer the AI worry early.Buyers feared AI would replace expert judgement. Say plainly where your experts stay in charge.
- Segment by role and by size.QA and the C-suite worry about different things, and so do small and large companies.
- Research and segment before you send.Their own LinkedIn messages and articles were not reaching decision makers. A researched, segmented campaign did.
Photo: Melany @ tuinfosalud.com, on Unsplash. Map: Natural Earth. Benchmarks: HeyReach 2026.

Selling into European pharma? Let’s look at it together.
A free 30-minute Outbound Review. We look at your market, your buyers and your current outreach, and say plainly whether outbound can work there.